morphosys
Novartis to acquire MorphoSys AG for €2.7bn
February 6, 2024Business Services Novartis, Pharmacy, acquisition, morphosys
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma
August 3, 2020Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …
MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate
January 14, 2020Manufacturing and Production, Sales and Marketing Incyte, morphosys, pharma, tafasitamab
MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a …
Working Life Interview: Jean-Paul Kress, CEO of MorphoSys
January 13, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Working Life, feature, morphosys, pharma
With a medical doctorate as well as degrees in pharmacology and immunology under your belt, was your path always to …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Janssen and Genmab sued for patent infringement in US
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement
German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
GSK licences RA drug
June 5, 2013Research and Development, Sales and Marketing GSK, RA, morphosys
GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …
Pharma manufacturing news in brief
March 22, 2011Manufacturing and Production American Regent, Berkshire Hathaway, Cytovance, Intercell, Solagran, West Pharmaceutical Services, morphosys, pharma contract manufacturing
Lubrizol bought for $9.7 billion by Berkshire Hathaway, plus the latest pharma manufacturing and quality news. Berkshire Hathaway, run by …
Dr Lisa Rojkjaer, head of clinical development, MorphoSys
October 15, 2009Research and Development appointment, morphosys, research and development
MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development. Dr Rojkjaer joins MorphoSys from Novartis …
